On 30 April, Annovis Bio, a clinical-stage drug platform company developing novel treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson’s disease (PD), announced plans for a new Phase II clinical trial investigating its lead compound ANVS401 in AD and PD. ANVS401 is a small orally administrated brain penetrant inhibitor of neurotoxic proteins.
The company has received comments from the US Food and Drug Administration (FDA) and can advance with the launch of its Phase II clinical trial, expecting to enrol 68 people with AD and PD at 10 sites across the US. They will receive ANVS401 for one month. The clinical trial is planned to start enrolment in May. However, due to the COVID-19 pandemic, the recruitment may be delayed until this summer.
